BioAge Labs, Inc. (NASDAQ:BIOA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been assigned a consensus recommendation of “Moderate Buy” from the four analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $45.00.

A number of equities analysts have recently issued reports on BIOA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a report on Wednesday, February 4th. Oppenheimer initiated coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They issued an “outperform” rating and a $60.00 price objective for the company. Citigroup upped their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd.

BioAge Labs Stock Down 5.9%

Shares of NASDAQ:BIOA opened at $18.72 on Friday. The firm has a market cap of $671.11 million, a P/E ratio of -12.32 and a beta of 1.22. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00. The company’s 50-day moving average price is $19.64 and its two-hundred day moving average price is $12.06.

Insider Activity at BioAge Labs

In related news, insider Paul D. Rubin sold 7,433 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kristen Fortney sold 233,107 shares of BioAge Labs stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total value of $4,223,898.84. Following the completion of the sale, the chief executive officer owned 976,949 shares of the company’s stock, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 267,540 shares of company stock worth $4,895,168 over the last 90 days. Insiders own 20.82% of the company’s stock.

Institutional Investors Weigh In On BioAge Labs

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after buying an additional 171,426 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the second quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new stake in BioAge Labs during the 2nd quarter worth $60,000. Jefferies Financial Group Inc. acquired a new stake in BioAge Labs during the 2nd quarter worth $206,000. Finally, Stonepine Capital Management LLC raised its position in shares of BioAge Labs by 202.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after acquiring an additional 101,085 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.